modelBetamethasone
Extends from Pharmacolibrary.Drugs.ATC.A.A07EA04.
Information
| name: | Betamethasone | |
| ATC code: | A07EA04 | route: | oral |
| compartments: | 1 | |
| dosage: | 2 | mg |
| volume of distribution: | 1.5 | L |
| clearance: | 0.12 | L/h/kg |
| other parameters in model implementation | ||
Betamethasone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive effects. It is primarily used for the treatment of various inflammatory and autoimmune conditions, and is also used in the management of adrenal insufficiency. The A07EA04 ATC code refers specifically to its use as an intestinal anti-inflammatory/anti-infective agent. Betamethasone is approved for clinical use and is available in various formulations including oral, intravenous, intramuscular, and topical.
Pharmacokinetics
Pharmacokinetic parameters are estimated for healthy adults with oral administration, as no publication with direct PK parameters for betamethasone intestinal use (A07EA04) could be identified.
References
Krzyzanski, W, et al., & Jusko, WJ (2021). Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. Journal of pharmacokinetics and pharmacodynamics 48(2) 261–272. DOI:10.1007/s10928-020-09730-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/33389521
Krzyzanski, W, et al., & Jusko, WJ (2021). Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women. Journal of pharmacokinetics and pharmacodynamics 48(3) 411–438. DOI:10.1007/s10928-021-09755-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/33954911
Lim, SY, et al., & Heard, CM (2020). Mucoadhesive thin films for the simultaneous delivery of microbicide and anti-inflammatory drugs in the treatment of periodontal diseases. International journal of pharmaceutics 573 118860–None. DOI:10.1016/j.ijpharm.2019.118860 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31759104
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)